Albinterferon-alfa 2b: a new treatment option for hepatitis C

Bibliography

• Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67
   PubMed Web of Science ®Google Scholar
• Zeuzem S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat Clin Pract Gastroenterol Hepatol 2008;5:610-22
   PubMedGoogle Scholar
• Ge D, Fellay J, Thompson AJ, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401
   PubMed Web of Science ®Google Scholar
• Flisiak R, Parfieniuk A. Investigational drugs for hepatitis C. Expert Opin Investig Drugs 2010;19:63-75
   PubMed Web of Science ®Google Scholar
• Hezode C, Forestier N, Dusheiko G, Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Everson GT, Gordon SC, Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38
   PubMed Web of Science ®Google Scholar
• Kwo P, Lawitz E, McCone J, HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus Pegintron (peginterferon alfa-2b)/ribavirin in treatment- naive subjects with genotype-1 chronic hepatitis C [abstract 4]. J Hepatol 2009;50(Suppl 1):S4
   Google Scholar
• Lawitz E, Younossi ZM, Shiffman M, Randomized trial comparing systemic and local reactions to controlled-release interferon alpha2b and pegylated-interferon alpha2b in hepatitis C patients who failed prior treatment [abstract 628]. J Hepatol 2009;50(Suppl 1):S231
   Google Scholar
• Novozhenov V, Zakharova N, Vinogradova E, Phase 2 study of omega interferon alone or in combination with ribavirin in subjects with chronic hepatitis C genotype-1 infection [abstract 11]. J Hepatol 2007;46(Suppl 1):S8
   Google Scholar
• Lawitz E, Zaman A, Muir AJ, Interim results from a phase Ib dose-escalation study of 4 weeks of PEG-interferon lambda (PEG-rIL-29) treatment in subjects with hepatitis C virus (HCV) genotype 1 with prior virologic response and relapse to eginterferon alfa and ribavirin [abstract 170]. Hepatology 2008;48(Suppl 1):385A
   Google Scholar
• Pestka S. The interferons. 50 years after their discovery, there is much more to learn. J Biol Chem 2007;282:20047-51
   PubMed Web of Science ®Google Scholar
• Osborn BL, Olsen HS, Nardelli B, Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002;303:540-8
   PubMed Web of Science ®Google Scholar
• Balan V, Nelson DR, Sulkowski MS, Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C. Antivir Ther 2006;11:901-8
   PubMed Web of Science ®Google Scholar
• Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005;436:967-72
   PubMed Web of Science ®Google Scholar
• Bain VG, Yoshida EM, Kaita KD, Dynamics of interferon-specific gene expression in peripheral blood of interferon alfa-naive patients with genotype 1 chronic hepatitis C infection treated with albumin-interferon alfa. Hepatol Res 2006;35:256-62
   PubMed Web of Science ®Google Scholar
• Liu C, Zhu H, Subramanian GM, Anti-hepatitis C virus activity of albinterferon alfa-2b in cell culture. Hepatol Res 2007;37:941-7
   PubMed Web of Science ®Google Scholar
• Davis GL, Balan V, Sulkowski MS, A phase 1 study to evaluate the pharmacokinetics, safety, and tolerability of escalating doses of a novel recombinant human albumin-interferonalpha fusion protein (albuferon™) in subjects with chronic hepatitis C [abstract 490]. Hepatology 2002;36:285A
   Google Scholar
• Bain VG, Kaita KD, Yoshida EM, A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 2006;44:671-8
   PubMed Web of Science ®Google Scholar
• Balan V, Nelson DR, Sulkowski MS, A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther 2006;11:35-45
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Yoshida EM, Benhamou Y, Albinterferon alfa-2b dosed every two or four weeks in interferon-naive patients with genotype 1 chronic hepatitis C. Hepatology 2008;48:407-17
   PubMed Web of Science ®Google Scholar
• Bain VG, Kaita KD, Marotta P, Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. Clin Gastroenterol Hepatol 2008;6:701-6
   PubMed Web of Science ®Google Scholar
• Human Genome Sciences announces interim results of phase 2b monthly-dosing trial of Zalbin™ in patients with chronic hepatitis C. Nasdaq-HGSI, 24 March 2010
   Google Scholar
• Nelson DR, Rustgi V, Balan V, Safety and antiviral activity of albinterferon alfa-2b in prior non-responders with chronic hepatitis C. Clin Gastro Hepatol 2009;7:212-18
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Sulkowski M, Lawitz E, Efficacy and safety of albinterferon alfa-2b in combination with ribavirin in treatment naive, chornic hepatitis C genotype 1 (CHC G1) patients [abstract 1041]. J Hepatol 2009;50(Suppl 1):S377
   Google Scholar
• Nelson D, Benhamou Y, Chuang W, Efficacy and safety results of albinterferon alfa-2b in combination with ribavirin in interferon-alfa treatment naive patients with genotype 2 or 3 chronic hepatitis C [abstract 1042]. J Hepatol 2009;50(Suppl 1):S378
   Google Scholar
• Nelson DR, Benhamou Y, Chuang WL, Albinterferon alfa-2b for the treatment of patients with chronic hepatitis C infected with genotypes 2 or 3. Gastroenterology In press
   Google Scholar
• Novartis Europharm Ltd withdraws its marketing authorisation application for Joulferon (albinterferon alfa-2b). EMA/249301/2010, 19 April 2010
   Google Scholar
• Human Genome Sciences announces preliminary feedback from FDA on Zalbin™ BLA for chronic hepatitis C. Nasdaq-HGSI, 14 June 2010
   Google Scholar